BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 27539844)

  • 21. (68)Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human glioblastoma.
    Fan D; Zhang X; Zhong L; Liu X; Sun Y; Zhao H; Jia B; Liu Z; Zhu Z; Shi J; Wang F
    Bioconjug Chem; 2015 Jun; 26(6):1054-60. PubMed ID: 25853280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer.
    Sun H; England CG; Hernandez R; Graves SA; Majewski RL; Kamkaew A; Jiang D; Barnhart TE; Yang Y; Cai W
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2169-2179. PubMed ID: 27342417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantification of Cerenkov Luminescence Imaging (CLI) Comparable With 3-D PET Standard Measurements.
    Habte F; Natarajan A; Paik DS; Gambhir SS
    Mol Imaging; 2018; 17():1536012118788637. PubMed ID: 30043654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
    Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
    Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerenkov Luminescence Imaging (CLI) for cancer therapy monitoring.
    Xu Y; Liu H; Chang E; Jiang H; Cheng Z
    J Vis Exp; 2012 Nov; (69):e4341. PubMed ID: 23183774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
    Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
    Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
    Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
    J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation Protection and Occupational Exposure on
    Costa PF; Fendler WP; Herrmann K; Sandach P; Grafe H; Grootendorst MR; Püllen L; Kesch C; Krafft U; Radtke JP; Tschirdewahn S; Hadaschik BA; Darr C
    J Nucl Med; 2022 Sep; 63(9):1349-1356. PubMed ID: 34916249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution.
    Tolmachev V; Malmberg J; Estrada S; Eriksson O; Orlova A
    Int J Oncol; 2014 Jun; 44(6):1998-2008. PubMed ID: 24718894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
    Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
    Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.
    Ruggiero A; Holland JP; Hudolin T; Shenker L; Koulova A; Bander NH; Lewis JS; Grimm J
    J Nucl Med; 2011 Oct; 52(10):1608-15. PubMed ID: 21908391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting.
    Mukherjee A; Kumar B; Hatano K; Russell LM; Trock BJ; Searson PC; Meeker AK; Pomper MG; Lupold SE
    Mol Cancer Ther; 2016 Oct; 15(10):2541-2550. PubMed ID: 27486224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
    Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
    J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
    Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
    Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiochemistry and Preclinical PET Imaging of
    Gourni E; Del Pozzo L; Bartholomä M; Kiefer Y; T Meyer P; Maecke HR; Holland JP
    Mol Imaging; 2017; 16():1536012117737010. PubMed ID: 29098927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
    Foss CA; Mease RC; Fan H; Wang Y; Ravert HT; Dannals RF; Olszewski RT; Heston WD; Kozikowski AP; Pomper MG
    Clin Cancer Res; 2005 Jun; 11(11):4022-8. PubMed ID: 15930336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.
    Cheal SM; Ruan S; Veach DR; Longo VA; Punzalan BJ; Wu J; Fung EK; Kelly MP; Kirshner JR; Giurleo JT; Ehrlich G; Han AQ; Thurston G; Olson WC; Zanzonico PB; Larson SM; Carrasquillo JA
    Mol Pharm; 2018 Jun; 15(6):2133-2141. PubMed ID: 29684277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
    Wang S; Li J; Hua J; Su Y; Beckford-Vera DR; Zhao W; Jayaraman M; Huynh TL; Zhao N; Wang YH; Huang Y; Qin F; Shen S; Gioeli D; Dreicer R; Sriram R; Egusa EA; Chou J; Feng FY; Aggarwal R; Evans MJ; Seo Y; Liu B; Flavell RR; He J
    Clin Cancer Res; 2021 Mar; 27(5):1305-1315. PubMed ID: 33293372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
    Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM
    J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative preclinical evaluation of
    Trencsényi G; Dénes N; Nagy G; Kis A; Vida A; Farkas F; Szabó JP; Kovács T; Berényi E; Garai I; Bai P; Hunyadi J; Kertész I
    J Pharm Biomed Anal; 2017 May; 139():54-64. PubMed ID: 28273651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.